Teva wins US FDA approval for Xgeva biosimilar DEGEVMA

FDA clearance covers DEGEVMA (denosumab-adet) as a biosimilar to Amgen's Xgeva. Teva said U.S. launches for DEGEVMA and PONLIMSI are expected in coming months.